focus -WSS

focus

author：comprehensive 2025-09-06 04:37:26 - browse：73

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： In Spain, a hospital brews its own CAR

WSS

After gene therapy, two congenitally deaf children hear for the first time

Brain worms: The science behind RFK Jr.'s parasitic infection

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Steward Health Care files for bankruptcy

HCA sued by state AG for quality issues at Mission Health

Medicare drug price negotiation hasn't dried up venture capital

hotspot

focus

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Hollywood unions extend contract negotiations for actors

CRISPR gene editing developments we’re watching in 2024

Moonlake's readout produced a cash windfall. Risks remain

Virtual care provider acquires bankrupt Pear's prescription apps

Virginia high school admissions case could be legal follow

Readout LOUD podcast: What to know about H5N1 bird flu

As demand for Covid shots wanes, Moderna seeks its next success

Hospitals owned by private equity see complications spike 25%

Wikipedia

In Spain, a hospital brews its own CAR

Editas, Vertex strike deal on CRISPR

Christmas in the PICU brings some surprising joy

Medicare says breakthrough device reimbursement rule to come by summer

Medicare Advantage beneficiaries sue Humana over algorithm use

Drinking less cuts risk of oral cavity, esophageal cancer: Report

entertainment

leisure time

focus

hotspot